Latest Gilead Sciences News & Updates

See the latest news and media coverage for Gilead. We track all announcements, press releases, and industry mentions in real time, all in one place.

Gilead Sciences (Gilead)

Biopharmaceutical company focused on virology, oncology and inflammation

gilead.com

Headquarters: Foster City, United States
Founded year: 1987
Company type: Public company
Number of employees: 10,000+

Last updated Today

Latest news about Gilead Sciences (Gilead)

In short: Gilead reported strong revenue growth, achieved major regulatory milestones for HIV and liver disease, and expanded its portfolio via acquisitions.

Company announcements

June 15 Gilead

Gilead's once-weekly oral HIV prevention pill application accepted

The FDA assigned a PDUFA date of February 2, 2027, and if approved, it would be the first long-acting oral PrEP option.

June 12 Gilead

Gilead donates remdesivir to support Ebola response in Uganda

The donation of over 2,000 vials will aid in treating the Ebola Bundibugyo virus disease under compassionate use.

June 8 Gilead

Gilead and Merck announce positive Phase 3 results for islatravir/lenacapavir

The once-weekly oral HIV treatment met primary endpoints in two trials, showing non-inferiority to BIKTARVY and standard of care.

June 4 Gilead

Gilead acquires Ouro Medicines to expand inflammation pipeline

The $1.675B deal adds a BCMAxCD3 T cell engager for autoimmune diseases and includes collaboration with Lakefront.

Media coverage

Yesterday GuruFocus

Insider Sell: Johanna Mercier Sells 3,000 Shares of Gilead Scien

Following this transaction, the insider now owns 124,234 shares of the company. Gilead Sciences Inc (GILD) is a biopharmaceutical company that discovers, develops, and commercializes...

June 16 Investing.com

Gilead Sciences CFO Andrew Dickinson sells stock worth $376,200 By Investing.com

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks...

June 15 Pharmaphorum

FDA starts kicks off review of Gilead's weekly HIV pill

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by...

June 15 Seeking Alpha

Gilead weekly Yeztugo HIV pill sNDA accepted by FDA

Gilead's weekly Yeztugo (lenacapavir) for HIV PrEP has been accepted for FDA review with a Feb. 2, 2027 action date.

Never miss news about Gilead

Track Gilead and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Gilead competitors & trending companies

Browse news for competitors to Gilead and other trending companies.